Stockscreener 앱 받기
18.94
1.35%
-0.26
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Summit Therapeutics to Present at Upcoming Investor Conferences - BioSpace
3 Monster Stocks in the Making - The Motley Fool
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN
Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why - Insider Monkey
Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright - MarketBeat
(SMMT) Trading Report - Stock Traders Daily
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics - Investor's Business Daily
Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters
Has Summit Therapeutics Stock Already Peaked? - AOL
2 Stocks Up Over 700% in 2024 That Could Soar Even Further - AOL
2 Hot Biopharma Stocks to Buy and Hold for 5 Years - AOL
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga
Is Summit Therapeutics a Millionaire Maker? - AOL
Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Why Summit Therapeutics Stock Was a Winner Today - MSN
Trading (SMMT) With Integrated Risk Controls - Stock Traders Daily
SMMT Surges as Analyst Initiates Coverage with Buy Rating - GuruFocus.com
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Yahoo Finance UK
Summit Therapeutics Leads the Parade of Big Gainers - GuruFocus.com
Summit Therapeutics shares rated Market Outperform by JMP Securities - Investing.com UK
Summit Therapeutics Leads The Parade Of Big Gainers - Forbes
Summit Therapeutics (NASDAQ:SMMT) Earns Market Outperform Rating from Analysts at JMP Securities - MarketBeat
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - MSN
abrdn plc Invests $24.89 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
H.C. Wainwright cuts Summit Therapeutics stock target, maintains Buy amid study expansion - Investing.com Canada
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Price Target Cut to $44.00 by Analysts at HC Wainwright - MarketBeat
Summit Therapeutics Inc. (NASDAQ:SMMT) Q3 2024 Earnings Call Transcript - Insider Monkey
Summit Therapeutics Posts Wider-Than-Expected Loss in Q3, Nil Sales - Yahoo Finance
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Summit Therapeutics reports Q3 EPS (5c), consensus (7c) - MSN
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insigh - GuruFocus.com
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight - Yahoo Finance
Summit Therapeutics Advances NSCLC Trials and Strengthens Financials - TipRanks
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 10.4%What's Next? - MarketBeat
Summit Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024 - BioSpace
China Universal Asset Management Co. Ltd. Purchases 56,879 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Tesla, Xpeng, Summit Therapeutics lead Monday's morning market cap stock movers - Investing.com Australia
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - StockTitan
0.87%
자본화:
|
볼륨(24시간):